Spelling suggestions: "subject:"anda combination therapy"" "subject:"anda cfombination therapy""
51 |
Development and evaluation of an oral fixed–dose triple combination dosage form for artesunate, dapsone and proguanil / van der Merwe, A.J.Van der Merwe, Adriana Johanna January 2011 (has links)
Malaria is a life–threatening disease caused by Plasmodium spp and causes over one million
deaths annually. The complex life cycle of the malaria parasite offers several points of attack
for the antimalarial drugs. The rapid spread of resistance against antimalarial drugs, especially
chloroquine and pyrimethamine–sulphadoxine, emphasises the need for new alternatives or
modification of existing drugs. Artemisinin–based combination therapies (ACT’s) with different
targets prevent or delay the development of drug resistance and therefore have been adopted
as first–line therapy by all endemic countries. Proguanil–dapsone, an antifolate combination is
more active than pyrimethamine–sulphadoxine and is being considered as an alternative to
pyrimethamine–sulphadoxine. Artesunate–proguanil–dapsone is a new ACT that has wellmatched
pharmacokinetics and is relatively rapidly eliminated; therefore there is a reduced risk
of exposure to any single compound and potentially a decreasing risk of resistance. A few
studies have been done on a triple fixed–dose combination therapy for malaria treatment and
such a combination for artesunate, proguanil and dapsone are not currently investigated,
manufactured or distributed. The aim of this study was to develop a triple fixed–dose
combination for artesunate, proguanil and dapsone.
The formulation was developed in three phases; basic formulation development, employing
factorial design to obtain two possible optimised formulations and evaluating the optimised
formulations. During the formulation development the most suitable manufacturing procedure
and excipients were selected. A full 24 factorial design (four factors at two levels) was used to
obtain the optimised formulations. As end–points to identify the optimised formulations, weight
variation, friability, crushing strength and disintegration of the tablets, were used. Statistical
analysis (one way ANOVA) was used to identify optimal formulations. To identify any
interaction between the active pharmaceutical ingredients (API’s) and the API’s and excipients,
differential scanning calorimetry was done. Flow properties of the powder mixtures (of the
optimised formulations) were characterised by means of angle of repose; critical orifice diameter
(COD); bulk density and tapped density; and flow rate. Tablets of the two optimised powder
formulations were compressed. The tablets were evaluated and characterised in terms of
weight variation, friability, crushing strength, disintegration and dissolution behaviour. Initial
formulation development indicated that wet granulation was the most suitable manufacturing method. The results from the factorial design indicated that different amounts (% w/w) of the
lubricant and binder as well as two different fillers influenced the weight variation, crushing
strength and disintegration statistically significant. Two formulations containing two different
fillers (microcrystalline cellulose or Avicel® PH 101, and lactose or Granulac® 200) were found to
be within specifications and ideal for manufacturing.
Tablets prepared from the FA formulation (formulation containing Avicel® PH 101) complied with
the standards and guidelines for weight variation, friability, crushing strength and disintegration
as set by the British Pharmacopoeia (BP). Tablets had an average crushing strength of 121.56
± 0.022 N. Tablets disintegrated within 52.00 seconds and a maximum weight loss of 0.68%
occurred during the friability test. Weight variation of the tablets prepared from the FG
formulation (formulation containing Granulac® 200) complied with the standards. Average
crushing strength was 91.99 ± 6.008 N and the tablets disintegrated within 140.00 seconds.
Percentage friability (1.024%) did not comply with the guideline of a percentage friability of less
than 1%, however, no cracked or broken tablets were seen.
Dissolution showed that 98, 93 and 94% of artesunate, proguanil and dapsone were
respectively released (of the label value) within 15 minutes for the FA formulations. Release of
artesunate, proguanil and dapsone for the FG formulation was 62, 85 and 92% for the same
time period. The release of the three API’s (the FG formulation) increased to 78, 89 and 92%, respectively, after 45 minutes. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2012.
|
52 |
Studium vlivu vybraných inhibitorů proteinkináz na lékovou rezistenci zprostředkovanou cytochromy P450 / Study on impact of selected protein kinase inhibitors on drug resistance mediated by cytochromes P450Janoušková, Adéla January 2019 (has links)
Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology & Toxicology Student: Adéla Janoušková Supervisor: RNDr. Jakub Hofman, Ph.D. Title of diploma thesis: Study on impact of selected protein kinase inhibitors on drug resistance mediated by cytochromes P450 Pharmacokinetic drug resistance often leads to failure of an anticancer therapy. One of the mechanisms is increased efflux of drugs from tumour cells, whereas some studies suggest that increased drug conversion to an inactive metabolite might be another contributing mechanism. The aim of this work was to define the possible role of CYP3A4 and CYP2C8 enzymes in the phenomenon of pharmacokinetic resistance and to investigate the possibility of its modulation by new targeted drugs. In the first part, we used the MTT proliferation method together with HepG2 cells stably transduced with particular human enzymes and demonstrated significant involvement of CYP3A4 in docetaxel resistance. In the following part, we examined the inhibitory effects of four selected tyrosine kinase inhibitors on the CYP3A4 activity in intact cells using a commercial kit. Cobimetinib and dabrafenib showed significant inhibitory activity, while osimertinib and brivanib did not. In the final part, we demonstrated the ability of the first two...
|
53 |
Predicting toxicity caused by high-dose-ratebrachytherapy boost for prostate cancerEstefan, Dalia January 2019 (has links)
Introduction Treating localized prostate cancer with combination radiotherapy consisting ofexternal beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDR-BT) has beenproven to result in better disease outcome than EBRT only. There is, however, a decreasingtrend in utilization of combination therapy, partially due to concerns for elevated toxicityrisks. Aim To determine which parameters correlate to acute and late (≤ 6 months) urinary toxicity(AUT and LUT) and acute and late rectal toxicity (ART and LRT), and thereafter createpredictive models for rectal toxicity. Methods Data on toxicity rates and 32 patient, tumor and treatment parameters were collectedfrom 359 patients treated between 2008 and 2018 with EBRT (42 Gy in 14 fractions) andHDR-BT (14.5 Gy in 1 fraction) for localized prostate cancer at Örebro University Hospital.Bivariate analyses were conducted on all parameters and the outcome variables AUT, LUT,ART and LRT grade ≥ 1, graded according to the RTOG-criteria. Parameters correlating toART and LRT in this and previous studies were included in multivariate logistic regressionanalyses for creation of predictive models. Results Most toxicities, 86%, were of grade 0 or 1, only 9% of patients had grade 2 – 3toxicity. Only 2 – 4 parameters correlated to the respective toxicities in bivariate analyses.Logistic regressions generated no significant predictors of ART or LRT. Therefore, nopredictive models were obtained. Conclusion None of the included parameters have enough discriminative abilities regardingrectal toxicity. Predictive models can most probably be obtained by including otherparameters and more patients.
|
54 |
Investigation of Polymeric Composites for Controlled Drug ReleaseYeh, Hsi-wei 01 January 2017 (has links)
The Electrospray (ES) technique is a promising particle generation method for drug delivery due to its capabilities of producing monodisperse PLGA composite particles with unique configurations and high drug encapsulation efficiency. In the dissertation work, the coaxial dual capillary ES was used to generate drug-loaded core-shell PLGA particles to study the effects of particle filling materials, drug loading locations and particle shell thicknesses on the resultant in vitro release behaviors of the hydrophilic and/ or hydrophobic model drugs. Through release profile characterization of drug-loaded PLGA particles (particle size: 400 nm and 1 μm), it was confirmed that the co-encapsulation of Budesonide (BUD, the hydrophobic small-molecule model drug) and Theophylline (THY, the hydrophilic small-molecule model drug) in the particle cores is the most effective drug loading strategy for extended release of the fixed combined BUD and THY. Particles composed of PLGA fillers with lower molecular weights and with greater shell layer thicknesses could release THY in a well controlled fashion. On the other hand, a slower release rate of Bovine Serum Albumin (BSA, the protein model drug) from PLGA particles with greater shell thickness was also observed. Sequential release of BSA and Paclitaxel (PTX, the hydrophobic small-molecule anti-cancer model drug) was achieved by the 400-nm PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particles with potential biopharmaceutical applications in cancer therapy.
|
55 |
Antigen Specific Induced T Regulatory Cellular Therapy for Graft-Versus-Host Disease Following Allogeneic Bone Marrow TransplantationHeinrichs, Jessica Lauren 20 January 2016 (has links)
Allogeneic hematopoietic stem cell transplantation (allo-HCT) has been a successful cellular therapy for patients suffering from hematological malignancies for many decades; however, the beneficial effects of graft-versus-leukemia (GVL) are classically offset by graft-versus-host disease (GVHD). GVHD occurs when major and/or minor human leukocyte antigen (HLA) mismatches between donor and recipient cause rapid expansion and activation of donor effector T cells (Teffs) resulting in end organ damage to the recipient’s epithelial tissues. Given the lymphoproliferative nature of this disease, the standard treatment option is broad immunosuppression, which can result in primary disease relapse, steroid refractory GVHD, and/or opportunistic infection. A more targeted therapy that can selectively suppress GVH responses with maintained GVL responses would achieve the optimal goal of allo-HCT. Regulatory T cells (Tregs) both natural (nTregs) or induced (iTregs) could be potential cellular therapies for the treatment of GVHD, given their innate suppressive function. Initial clinical trials using nTregs have yielded positive results; however, nTreg cellular therapy has been cumbersome due to the necessity for large scale ex vivo expansion given their low yield within an apheresis product and non-specific suppression. Conversely, iTregs can be generated from naïve T cells thus decreasing ex vivo culture times and can be educated with specific antigen thus providing targeted suppression, but a consensus on their efficacy for GVHD therapy has not been reached. Therefore, we investigated the efficacy of antigen specific iTreg therapy for the prevention of GVHD while maintaining GVL responses.
In Chapter 2, we evaluated the effectiveness of monoclonal HY-specific iTregs in GVHD attenuation. We chose HY as a target antigen because it is a naturally processed, ubiquitously expressed minor mismatch antigen carried by only male donors/recipients cited to increase GVHD prevalence when donor and recipient are sex-mismatched. Utilizing HY-transgenic mice in which all T cells recognize HY antigen exclusively, we generated HY specific iTregs which effectively attenuating GVHD in male, but not female recipients in three murine bone marrow transplantation (BMT) models (major mismatch, parent to F1, and miHAg mismatch). We found HY specific iTregs lost stability in female recipients but remained stable and suppressive in male recipients suggesting expression of HY antigen was required for their suppressive function and stability. GVL responses were not compromised with the addition of HY specific iTregs in recipient mice using a pre-established tumor model. Thus, HY-specific iTregs can be generated and suppress GVHD in an antigen-dependent manner while sparing the GVL effect.
In Chapter 3, we extend our findings in Chapter 2, which provided proof of principle that antigen specific iTregs effectively control GVHD; however, this therapy has a limited translational potential. Therefore, we generated alloreactive CD4 and CD8 iTregs and evaluated GVHD attenuation and GVL preservation in either full or haplo-MHC mismatched BMT models. We found alloreactive CD4 iTregs significantly suppress lethal GVHD, but completely abrogated the GVL effect against aggressive tumors. Conversely, alloreactive CD8 iTregs moderately attenuated GVHD and possessed direct cytotoxicity against tumor cells. Therefore, to rescue the impaired GVL effect mediated by CD4 iTregs, we established a combinational therapy with CD8 iTregs. Indeed we found combination CD4 and CD8 iTreg therapy significantly suppressed GVHD while sparing GVL responses compared to either CD4 or CD8 singular therapy. Mechanistically, this was achieved by potent suppression of both CD4 and CD8 Teffs coupled with preserved cytolytic molecule expression by both CD8 iTregs and Teffs.
Taken together, we propose antigen specific iTreg therapy can effectively attenuate GVHD while preserving GVL responses. We further uncovered unique characteristics of CD4 and CD8 iTregs that can be exploited to achieve the optimal cellular therapy following allo-HCT.
|
56 |
Antibiotic combination therapies against carbapenamse producing Klebsiella pneumoniaeSöderhäll, Thomas January 2021 (has links)
The treatment options for multidrug resistant bacteria are dwindling and it is an important issue of research in medicine to solve. One of the more problematic bacterial species is Klebsiella pneumoniae, it can cause infections with high morbidity that are difficult to treat. Common antibiotics for treatment of these infections are carbapenems but K. pneumoniae can produce enzymes called carbapenemases that can hydrolyze carbapenems and most other beta-lactam antibiotics. In this study carbapenemase genes were introduced chromosomally to a previously susceptible K. pneumoniae strain using λ-Red recombineering. Further constructs were made with non-functional porins to examine how they affect combination treatment with carbapenems. Antibiotic combination therapy was evaluated against constructed carbapenemase- (KPC-2, NDM-1 and OXA-48) producing K. pneumoniae strains. Screening was done using time-lapse microscopy (oCelloScope), and combinations with better effect than treatment with a single antibiotic were chosen for time-kill assays. The results shows that a triple combination of colistin, meropenem and the beta-lactamase inhibitor avibactam gives an improved effect, up to twice the effect compared to monotherapy and up to 1.8 times increased effect compared to double combination. The synergistic effect was greater when adding colistin to treat the strains with non-functional porins, indicating that colistin can increase the permeability for other antibiotics into the cell. This is an interesting finding that need to be researched further.
|
57 |
Improving breast cancer therapy through oestrone analogue and glycolysis inhibitor synergismAnderson, Roxette Dianne January 2017 (has links)
Introduction: In South Africa, breast cancer has the highest prevalence with a life time risk of
1 in every 9 women being diagnosed annually. There are four sub-types of breast cancer and
according to the stage of the cancer, various treatment regimens are prescribed. A major obstacle
is that majority of cancers have developed multi-drug resistance and new treatment regimens
need to be developed in order to obtain therapeutic efficacy. Cancer cells use aerobic glycolytic
metabolism for energy generation and inhibition of this pathway increases sensitivity of the cells
to anti-neoplasic treatments. 2-Deoxyglucose (2-DG) competes with and inhibits glucose uptake
inhibiting the glycolytic pathway which can result in depolarisation of the mitochondrial
membrane potential releasing cytochrome c. Two 2-Methoxyestradiol (2-ME) derivatives, ESE-
15-ol and ESE-16 have shown to be promising anti-cancer agents and combination therapy could
allow the use of these compounds with a decreased side effect profile. The combination of these
compounds with 2-DG was therefore investigated.
Aim: To investigate combinations of two oestrone analogues and the glycolysis inhibitor 2-
deoxyglucose for potential synergistic effects using a cell enumeration assay, mitochondrial
membrane potential and cell cycle analysis, on breast cancer cells in an in vitro setting. Cell
apoptosis, necrosis and autophagy pathways were assessed to indicate the mechanism of
cytotoxicity.
Methods: The breast cancer MCF-7 and non-tumorigenic MCF-12A cell line were used. Cells
were exposed to ESE-15-ol, ESE-16 and 2-DG alone and in combination. Mechanistic studies
were performed using the various research methodologies including the sulforhodamine B assay
for cell enumeration, Annexin-V FITC and propidium iodide labeling for apoptosis/necrosis
studies, PlasDIC and light microscopy for morphological analysis, propidium iodide staining for
cell cycle progression, JC-1 for mitochondrial membrane potential studies, transmission electron
microscopy and western blotting for the analysis of autophagy.
Results: A GI50 of 34.1 nM was reported for MCF-7 cells after treatment with ESE-15-ol, 141
nM for ESE-16 and 1.3 mM 2-DG. The GI50 of ESE-15-ol treated MCF-12A cells was 141 nM,
140.1 nM for ESE-16 treated cells and 1.7 mM for 2-DG. ESE-16 had the greatest effect on cell
viability in MCF-7 cells and a shift from an inhibitory effect to the initiation of cell death was
evident after treatment of 100 nM of ESE-15-ol and ESE-16. 2-DG had a lower cytotoxic effect
than the oestrone analogues. The MCF-12A cell line was less susceptible to the experimental
compounds. The combination of the oestrone analogues with 2-DG elicited a greater effect on cell enumeration than each of the compounds alone with a less pronounced effect on the MCF-
12A cell line in comparison to the MCF-7 cells. The experimental compounds initiated apoptosis
with ESE-16 eliciting a greater effect than ESE-15-ol. The combination of the oestrone analogues
with 2-DG resulted in increased apoptosis in contrast to the compounds alone. ESE-16 alone and
in combination with 2-DG lead to the most prominent morphological changes, with ESE-15-ol
decreasing cell density slightly. The combination of ESE-15-ol with 2-DG decreased cell density
with membrane blebbing apparent. The MCF-12A cell line was less susceptible to morphological
changes after treatment of ESE-15-ol with 2-DG however ESE-16 and the combination with 2-
DG resulted in similar attributes seen in MCF-7 treated cells. ESE-15-ol resulted in accumulation
of cells in the G2 cell cycle phase which was further amplified after the combination of 2-DG.
A sub-G1 accumulation was observed after treatment with ESE-16 with a shift to a G2
accumulation after the combined treatment of ESE-16 with 2-DG. After 48 hours, ESE-15-ol
alone and in combination with 2-DG on MCF-7 cells resulted in depolarisation of the
mitochondrial membrane. A slight decrease in the membrane potential was observed after
treatment with ESE-16 and this was further increased after the combined treatment of ESE-16
with 2-DG. The MCF-12A were less susceptible after 24 hour treatment than 48 hour exposure
of the experimental compounds. The presence of autophagic-like vacuoles were apparent in all
treatment groups as well as the increased expression of LC3-II.
Conclusion: The combined treatment of synthetic oestrone analogues with 2-DG displayed
greater therapeutic efficacy than each of the compounds alone. As a result, the apoptotic and
autophagic pathways were induced and a shift in cell cycle progression was observed.
Mitochondrial involvement was apparent and the compounds significantly affected cell viability.
This suggests that the combinations between the antimitotic oestrone analogues and glycolysis
inhibitor 2-DG act synergistically to induce apoptosis and autophagy in MCF-7 breast cancer
cells. / Dissertation (MSc)--University of Pretoria, 2017. / Pharmacology / MSc / Unrestricted
|
58 |
Pokročilé testování antibakteriální aktivity kandidátních nově syntetizovaných sloučenin / Advanced antibacterial activity testing of candidate newly synthesized compoundsNovotná, Simona January 2020 (has links)
Charles University in Prague Faculty of Pharmacy in Hradec Králové Department of Biological and Medical Sciences Study program: Pharmacy Author: Simona Novotná Supervisor: RNDr. Klára Konečná, Ph.D. Title of diploma thesis: Advanced antibacterial activity testing of candidate newly synthesized compounds Background: The aim of this thesis was to perform an extended study of the antibacterial activity of selected newly synthesized rhodanine derivatives. In this study, activity against clinical isolates of bacterial strains of the genus Staphylococcus and Enterococcus was evaluated. The main part of the work also includes the evaluation of the antibacterial activity of one selected substance in combination with commercially available antibiotics using the checkerboard method. Methods: Evaluation of the antibacterial activity of tested substances was performed using the broth microdilution method according to EUCAST guidelines (with minor modifications). The activity of these substances was evaluated against clinical isolates of bacteria of the genera Staphylococcus and Enterococcus and one Staphylococcus aureus MRSA reference strain (ATCC 43300, CCM 4750). For a selected compound with a demonstrably promising antistaphylococcal effect, the combined effect of this substance was tested with three...
|
59 |
Preparation and Characterization of Polymersomes for Nose-to-Brain Delivery of Combination Therapeutics in Neuroinflammation TreatmentManickavasagam, Dharani 25 April 2019 (has links)
No description available.
|
60 |
ROR1 Targeted Therapy in Small Cell Lung CancerWang, Walter Z. 11 August 2022 (has links)
No description available.
|
Page generated in 0.0928 seconds